RxDoctor Payments Data

Brandon Genson, DO

Internal Medicine · Highland, MINPI 1548585045

Payments from drug & device makers

$6,558in general payments, 2019–2025

Across 375 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$924
  • AstraZeneca$619
  • Pfizer$578
  • AbbVie$545
  • GSK$493
  • Lilly USA, LLC$372
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,51799%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,558 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$179,887
Medicare patients
487
Services billed
2,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$128,262
Humira PenAdalimumab16$114,085
OzempicSemaglutide60$83,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$49,973
XareltoRivaroxaban29$42,890
FarxigaDapagliflozin Propanediol13$21,518
JardianceEmpagliflozin14$21,218
EntrestoSacubitril/Valsartan11$19,016
TrulicityDulaglutide17$18,640
MounjaroTirzepatide17$17,069
CreonLipase/Protease/Amylase11$16,456
Breo ElliptaFluticasone/Vilanterol11$8,769
BrilintaTicagrelor11$7,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$4,790
Atorvastatin Calcium293$4,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$578$128,26293 claims
Novo NordiskOzempic$924$83,02360 claims
GSKTrelegy Ellipta, Breo Ellipta$493$58,74250 claims
Lilly USA, LLCTrulicity, Mounjaro$372$35,70834 claims
AstraZenecaFarxiga, Brilinta$619$28,76424 claims
Boehringer IngelheimJardiance$87$21,21814 claims
NovartisEntresto$370$19,01611 claims
AbbVieCreon, Synthroid$545$18,36228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Highland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →